NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68382-0641-16 | 68382-0641 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 16, 2018 | Apr 26, 2019 | No Longer Used |
70518-1704-01 | 70518-1704 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 19, 2024 | In Use | |
61919-0733-90 | 61919-0733 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 18, 2019 | In Use | |
00006-4045-00 | 00006-4045 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jun 8, 2006 | In Use | |
72865-0140-30 | 72865-0140 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 9, 2020 | In Use | |
52125-0606-19 | 52125-0606 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Sep 19, 2013 | Sep 19, 2013 | No Longer Used | |
00006-4109-02 | 00006-4109 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | 40.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Jun 8, 2006 | In Use | |
52152-0500-30 | 52152-0500 | Finasteride | Finasteride | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 28, 2007 | Sep 30, 2013 | No Longer Used | |
68788-9519-01 | 68788-9519 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 6, 2014 | May 21, 2020 | No Longer Used |
72578-0019-06 | 72578-0019 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Apr 15, 2019 | In Use | |
55150-0337-01 | 55150-0337 | BORTEZOMIB | BORTEZOMIB | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
63020-0079-02 | 63020-0079 | Ixazomib | Ninlaro | 3.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov 20, 2015 | Oct 31, 2023 | No Longer Used |
51817-0586-01 | 51817-0586 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
63020-0080-02 | 63020-0080 | Ixazomib | Ninlaro | 4.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov 20, 2015 | Oct 31, 2023 | No Longer Used |
50742-0484-01 | 50742-0484 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | In Use | |
70511-0162-02 | 70511-0162 | Bortezomib | Bortezomib | 2.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous | Aug 11, 2022 | In Use | |
72266-0243-01 | 72266-0243 | Bortezomib | Bortezomib | 1.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous | Aug 23, 2022 | Jun 30, 2024 | No Longer Used |
72266-0244-01 | 72266-0244 | Bortezomib | Bortezomib | 2.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous | Aug 23, 2022 | Jun 30, 2024 | No Longer Used |
63020-0078-02 | 63020-0078 | Ixazomib | Ninlaro | 2.3 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov 20, 2015 | Oct 31, 2023 | No Longer Used |
83090-0008-01 | 83090-0008 | Bortezomib | Bortezomib | 3.5 mg/3.5mL | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Jul 15, 2023 | In Use | |
72603-0270-01 | 72603-0270 | Bortexomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Nov 1, 2024 | In Use | |
70511-0161-05 | 70511-0161 | Bortezomib | Bortezomib | 1.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous | Aug 11, 2022 | In Use | |
72205-0183-01 | 72205-0183 | Bortezomib | Bortezomib | 3.5 mg/3.5mL | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Jul 27, 2022 | In Use | |
71288-0118-10 | 71288-0118 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Jul 26, 2022 | In Use | |
70771-1708-01 | 70771-1708 | BORTEZOMIB | BORTEZOMIB | 1.0 mg/mL | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use |
Found 11120 results — Export these results